Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2021 ASCO Annual Meeting
  • CME

June 4-8, 2021; Online at https://conferences.asco.org/am
Review expert perspectives on the most clinically relevant data on colorectal and gastroesophageal cancers presented at the 2021 ASCO Annual Meeting.
Manish A. Shah, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: July 27, 2021 Expiration: July 26, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with gastrointestinal cancers.
  • Identify subpopulations of patients with gastrointestinal cancers most likely to benefit from a specific treatment plan based on prognostic or predictive markers.
  • Discuss new data on novel agents and therapeutic approaches for patients with gastrointestinal cancers.
  • Consider how new trial findings might affect treatment of gastrointestinal cancers clinical practice in the future.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Chief,
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Manish A. Shah, MD, has disclosed that he has received funds for research support from Astellas, Bristol-Myers Squibb, and Merck.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with gastrointestinal cancers.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with gastrointestinal cancers.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 27, 2021, through July 26, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

DESTINY-Gastric02 trial: T-DXd demonstrated activity as second-line treatment in Western patients with HER2+ advanced gastric/GEJ cancer; from ESMO 2021 and Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 22, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Enter the characteristics of your patients with pancreatic cancer into this online tool from Clinical Care Options (CCO) to receive expert treatment recommendations

Andrew H. Ko, MD
Program Director
Elena Gabriela Chiorean, MD Dan Laheru, MD person default Paul E. Oberstein, MD Michael J. Pishvaian, MD, PhD
Released: September 13, 2021

From Clinical Care Options (CCO), download a PDF featuring expert discussion of biomarkers in gastrointestinal cancers

John L. Marshall, MD Released: August 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue